Cue Biopharma Inc

1UC

Company Profile

  • Business description

    Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

  • Contact

    40 Guest Street
    BostonMA02135
    USA

    T: +1 617 949-2680

    E: [email protected]

    https://www.cuebiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    41

Stocks News & Analysis

stocks

BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs

We plan to raise our fair value estimate of BlackRock stock.
stocks

Our view of ANZ’s strategic plan

Trying to please customers and shareholders with a simpler and leaner bank.
stocks

Perplexing buyback from overvalued ASX share

Earnings continue to grow but investor expectations are too high.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,299.0021.900.24%
CAC 408,095.20175.582.22%
DAX 4024,261.0524.110.10%
Dow JONES (US)46,623.77353.310.76%
FTSE 1009,439.2713.50-0.14%
HKSE25,910.60469.251.84%
NASDAQ22,754.12232.421.03%
Nikkei 22547,672.67825.351.76%
NZX 50 Index13,307.4030.410.23%
S&P 5006,706.3562.040.93%
S&P/ASX 2008,990.9022.200.25%
SSE Composite Index3,912.2146.981.22%

Market Movers